Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Frailty Syndrome and Its Associated Factors Among Elderly Patients (Frailty)

21. Juli 2026 aktualisiert von: Asma Ahmed Rafat Najeeb, Assiut University

Frailty Syndrome and Its Associated Factors Among Elderly Patients Attending Assiut University Hospitals

This is a cross-sectional analytical study conducted among elderly patients attending Assiut university hospital.

2.4. 2- Study Setting:The study will be conducted in Assiut University hospital, including outpatients and inpatients who fulfill inclusion criteria.

2.4. 3- Study subjects:

  • a. Inclusion criteria:
  • Age ≥ 60 years
  • Patient attending Assiut university hospital during the study period, regardless primary diagnosis.
  • Ability to provide informed consent and agreed to participate in the study.
  • Ability to communicate and answer the study questionnaire.
  • b. Exclusion criteria:
  • Age < 60 years
  • Patients admitted for elective surgical procedures or transferred from surgical wards
  • Patients with a terminal illness or those receiving palliative/end-of-life care only
  • Patients with incomplete medical records or inability to complete the assessment due to severe aphasia or critical hemodynamic instability
  • Patients with severe cognitive impairment or psychiatric disorders affecting communication.
  • Patients who refused to participate

    c. Sample Size Calculation: Based on determining the main outcome variable, the estimated minimum required sample size is 175 patients.

The sample size was calculated using Epi-Info version 7 software, based on the following assumptions:

Based on a previous study by Perez-Zepeda et al. (2023)(3), which reported a frailty prevalence of approximately 42% among hospitalized elderly patients using the Frailty Index with a deficit accumulation approach, Based on a confidence level of 90% and an absolute precision (confidence limit) of 5%.

2.4.4 Study tools:

The study will be done by using a semi structured questionnaire that will include four sections as follows:

Section I: Sociodemographic and Clinical Data Sheet:

A structured interviewer-administered data collection form will be used to record baseline sociodemographic and clinical characteristics of all enrolled patients. This will include age, sex, level of education, marital status, and place of residence. Clinical data will encompass the primary diagnosis on admission, all documented comorbidities, total number of regular medications (polypharmacy defined as the concurrent use of five or more medications), smoking history, and the number of hospital admissions within the preceding 12 months.

Section II: The 30-Item Frailty Index (FI):

Frailty will be assessed using a 30-item Frailty Index (FI) constructed in accordance with the deficit accumulation model originally proposed by Rockwood and Mitnitski. This model conceptualizes frailty as the cumulative burden of age-related health deficits across multiple physiological domains. Each deficit is coded as 0 (absent) or 1 (present); where a deficit is gradable in severity, an intermediate score of 0.5 is assigned. The FI is calculated by the following formula:

FI="Number of deficits present" /30

Participants are subsequently classified into three frailty categories according to their FI score:

FI Score Frailty Category < 0.10 Robust 0.10 - 0.24 Pre-frail

≥ 0.25 Frail

Section III. Physical examination and Anthropometric Measurements:

All participants will undergo a comprehensive physical examination including assessment of vital signs (blood pressure, pulse rate, respiratory rate, and body temperature), anthropometric measurements (weight, height and body mass index), and a systematic clinical examination relevant to the study objectives.

  • Body weight will be measured using calibrated digital scales, with the patient wearing light clothing and no shoes
  • Height will be measured using a wall-mounted stadiometer
  • BMI will be calculated accordingly Findings will be recorded in a standardized data collection sheet.

Section IV. Laboratory Investigations:

The following investigations will be collected from the routine admission workup or ordered as part of the study protocol:

  • Complete blood count (CBC) for hemoglobin and hematocrit
  • Serum albumin measured by colorimetric bromocresol green (BCG) method
  • Random blood glucose for diabetes assessment

Studienübersicht

Status

Noch keine Rekrutierung

Detaillierte Beschreibung

The 30-Item Frailty Index (FI):

Frailty will be assessed using a 30-item Frailty Index (FI) constructed in accordance with the deficit accumulation model originally proposed by Rockwood and Mitnitski. This model conceptualizes frailty as the cumulative burden of age-related health deficits across multiple physiological domains. Each deficit is coded as 0 (absent) or 1 (present); where a deficit is gradable in severity, an intermediate score of 0.5 is assigned. The FI is calculated by the following formula:

FI="Number of deficits present" /30

Participants are subsequently classified into three frailty categories according to their FI score:

FI Score Frailty Category < 0.10 Robust 0.10 - 0.24 Pre-frail

≥ 0.25 Frail

The 30 deficits are distributed across six sections as follows:

Section A: Chronic Diseases (10 items) The presence of each chronic disease is confirmed through a combination of patient interview, review of medical records, and available investigation results. The ten items are: hypertension (diagnosed and/or on antihypertensive therapy); diabetes mellitus (diagnosed and/or on antidiabetic treatment); ischemic heart disease (confirmed by electrocardiography, echocardiography, or documented medical history); heart failure (diagnosed clinically and/or by echocardiographic assessment of ejection fraction); atrial fibrillation (confirmed on 12-lead ECG or Holter monitoring); prior stroke or transient ischemic attack (documented cerebrovascular event in the medical record); chronic obstructive pulmonary disease or chronic lung disease (diagnosed by spirometry or clinical assessment); chronic kidney disease (estimated glomerular filtration rate below 60 mL/min/1.73m² for more than three months); chronic liver disease (confirmed by clinical, laboratory, or imaging findings); and active or prior malignancy (confirmed by histopathological report or documented in the clinical record).

Section B: General Symptoms (5 items):

These items are assessed through a structured patient interview. They include: unintentional weight loss, defined as a loss of more than 4.5 kg or more than 5% of body weight over the preceding year; persistent fatigue, defined as self-reported fatigue present most of the time for a duration of three or more months; chronic pain, defined as pain persisting beyond three months and requiring regular analgesia or limiting daily activity; dyspnea on exertion, graded using the Modified Medical Research Council (mMRC) Dyspnea Scale with a score of 2 or above considered positive; and poor appetite, defined as self-reported reduction in food intake over the preceding month.

Section C: Basic Activities of Daily Living - ADL (5 items):

Functional status with respect to basic self-care activities will be assessed using the Katz Activities of Daily Living (ADL) Scale. Dependency in any of the following activities will be coded as 1 (dependent) versus 0 (independent): bathing, dressing, toileting, transferring from bed to chair, and feeding. Pre-admission functional status will be recorded based on patient or caregiver recall to reflect the patient's baseline prior to the acute illness.

Section D: Instrumental Activities of Daily Living - IADL (4 items):

Higher-order functional independence will be assessed using the Lawton Instrumental Activities of Daily Living (IADL) Scale. The four items assessed are: ability to use a telephone, ability to shop, ability to prepare meals, and ability to manage medications. Each item is coded as 0 (independent) or 1 (dependent).

Section E: Cognition and Mood (3 items):

Cognitive status will be evaluated using the Mini-Mental State Examination (MMSE); a score below 24 will be coded as cognitive impairment (1). Depressive symptoms will be screened using the 15-item Geriatric Depression Scale (GDS-15); a score of 6 or above will be coded as depression (1). Subjective memory complaint, defined as self-reported difficulty with memory not fully captured by formal cognitive testing, will be recorded separately and coded as 0 (absent) or 1 (present).

Section F: Physical and Laboratory Indicators (3 items):

Three objectively measured indicators will be included. Anemia is defined according to World Health Organization (WHO) criteria as a hemoglobin level below 13 g/dL in men and below 12 g/dL in women, determined from the admission complete blood count. Hypoalbuminemia is defined as a serum albumin level below 3.5 g/dL, measured using the colorimetric bromocresol green (BCG) method on the admission blood sample. Abnormal body mass index (BMI) is defined as BMI below 18.5 kg/m² (underweight) or 30 kg/m² and above (obese); body weight will be measured using a calibrated digital scale with the patient in light clothing and without footwear, and height will be measured using a wall-mounted stadiometer.

Studientyp

Beobachtungs

Einschreibung (Geschätzt)

175

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

  • Name: Asma Ahmed Rafat, specialist
  • Telefonnummer: +201030533071
  • E-Mail: asmaacc@yahoo.com

Studieren Sie die Kontaktsicherung

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Erwachsene
  • Älterer Erwachsener

Akzeptiert gesunde Freiwillige

Nein

Probenahmeverfahren

Nicht-Wahrscheinlichkeitsprobe

Studienpopulation

elderly patients attending Assiut university hospital, including outpatients and inpatients who fulfill inclusion criteria.

Beschreibung

  • a. Inclusion criteria:
  • Age ≥ 60 years
  • Patient attending Assiut university hospital during the study period, regardless primary diagnosis.
  • Ability to provide informed consent and agreed to participate in the study.
  • Ability to communicate and answer the study questionnaire.
  • b. Exclusion criteria:
  • Age < 60 years
  • Patients admitted for elective surgical procedures or transferred from surgical wards
  • Patients with a terminal illness or those receiving palliative/end-of-life care only
  • Patients with incomplete medical records or inability to complete the assessment due to severe aphasia or critical hemodynamic instability
  • Patients with severe cognitive impairment or psychiatric disorders affecting communication.
  • Patients who refused to participate

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

Kohorten und Interventionen

Gruppe / Kohorte
• Patient attending Assiut university hospital during the study period aged above 60 years
  • a. Inclusion criteria:
  • Age ≥ 60 years
  • Patient attending Assiut university hospital during the study period, regardless primary diagnosis.
  • Ability to provide informed consent and agreed to participate in the study.
  • Ability to communicate and answer the study questionnaire.
  • b. Exclusion criteria:
  • Age < 60 years
  • Patients admitted for elective surgical procedures or transferred from surgical wards
  • Patients with a terminal illness or those receiving palliative/end-of-life care only
  • Patients with incomplete medical records or inability to complete the assessment due to severe aphasia or critical hemodynamic instability
  • Patients with severe cognitive impairment or psychiatric disorders affecting communication.
  • Patients who refused to participate

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
• Prevalence of frailty syndrome
Zeitfenster: Baseline
• Prevalence of frailty syndrome among elderly patients attending Assiut university hospital, defined as FI ≥ 0.25
Baseline

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Socio-demographic characteristics associated with frailty syndrome
Zeitfenster: Baseline
Assessment of age, gender, education level, living arrangement, and marital status collected via a structured questionnaire
Baseline

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Studienleiter: Dalia Galal Mahran, professor, Professor at Public Health and community medicine Department, Head of Family medicine department

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

20. Juli 2026

Primärer Abschluss (Geschätzt)

20. Juli 2027

Studienabschluss (Geschätzt)

20. Juli 2027

Studienanmeldedaten

Zuerst eingereicht

2. Juli 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

21. Juli 2026

Zuerst gepostet (Tatsächlich)

27. Juli 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

27. Juli 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

21. Juli 2026

Zuletzt verifiziert

1. Juli 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Schlüsselwörter

Andere Studien-ID-Nummern

  • Frailty Syndrome

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

UNENTSCHIEDEN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren